David Urech

David is the Chief Executive and Chief Scientific Officer and a co-founder of Numab. Prior to starting Numab, David was Head of Research & Development at ESBATech AG, where he conceived and implemented ESBATech’s antibody discovery platform. He was responsible for the discovery and preclinical development of brolucizumab/Beovu®, a VEGF-blocking antibody fragment for the treatment of age-related macular edema, recently launched by Novartis. David holds an MSc in Molecular Biology and Neurosciences from the University of Zurich, and a PhD in Biochemistry from the Biocenter in Basel.